The current binary classification of positive or negative HER2 status is evolving, and many patients formerly classified as HER2-negative are now considered HER2-low, and may benefit from HER2-targeted therapy. This highlights the importance of accurate biomarker assessment and interpretation to evaluate appropriate treatment options. Make sure you are ready to care for patients with HER2-low breast cancer! Tune in to hear recognized breast cancer experts in Part 2 of our Breast Cancer Hot Topics series discuss: the latest guidelines and expert insights on HER2 testing and interpretation evidence-based treatment options for patients with HER2-low breast cancer participate in gamified case challenges. This activity is delivered in partnership with After Breast Cancer Diagnosis (ABCD).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/emergence-new-subtype-her2-low-breast-cancer
- Start Date: 2024-08-02 05:00:00
- End Date: 2024-08-02 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 11250.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 11250.0 - Is Kind Support: False Source: Gilead Sciences, Inc. - Amount: 8291.67 - Is Kind Support: False Source: Merck (Any division) - Amount: 8333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology